Pfizer Submits Favorable Initial Data To The FDA On Kids’ COVID-19 Vaccine Trial

An older child gets vaccinated in Michigan. Pfizer and BioNTech say they will send an official request for emergency situation use authorization of the vaccine in kids as young as 5 in the coming weeks.

Emily Elconin/Bloomberg through Getty Images

toggle caption

hide caption

Emily Elconin/Bloomberg through Getty Images

An older child gets vaccinated in Michigan. Pfizer and BioNTech state they will send an official ask for emergency usage authorization of the vaccine in children as young as 5 in the coming weeks.

Emily Elconin/Bloomberg via Getty Images

Pfizer and BioNTech are another action better to looking for authorization for young kids to receive the COVID-19 coronavirus vaccine, submitting data to the Food and Drug Administration that reveals a “robust” antibody action and “favorable” safety results in kids ages 5 to 11 who got the two-dose regimen in medical trials. News of the data submission comes a week after Pfizer announced appealing outcomes from the trials, which have actually been carefully seen by moms and dads eager to safeguard their children from the coronavirus. Children received two vaccine dosages of 10 micrograms– especially smaller than the set of 30-microgram dosages used in an earlier successful trial for people 16 to 25 years old.

Pfizer and BioNTech are another step closer to seeking permission for young children to receive the COVID-19 coronavirus vaccine, submitting information to the Food and Drug Administration that reveals a “robust” antibody reaction and “beneficial” safety results in kids ages 5 to 11 who received the two-dose routine in scientific trials. News of the information submission comes a week after Pfizer announced promising outcomes from the trials, which have actually been closely watched by parents excited to safeguard their kids from the coronavirus. Kids got two vaccine dosages of 10 micrograms– especially smaller than the pair of 30-microgram dosages used in an earlier successful trial for people 16 to 25 years old.

The results of the two trials are comparable, the business stated as they announced the data submission to the FDA. In a separate medical trial for kids younger than 5, participants are receiving 3-microgram doses of the vaccine. The pharmaceutical business anticipate to have outcomes of trials for kids from 6 months as much as 2 years of ages and from ages 2 to 5 “as soon as the fourth quarter of this year.”

Leave a Reply

Your email address will not be published. Required fields are marked *